With the SEC Rule 13f-2 deadline fast approaching, is your firm confident its regulatory interpretation is in line with industry peers? The Endoxa consortium is methodically analyzing the complexities of SEC Rule 13f-2 and working to find clarity around common use cases. Learn how Droit’s Position Reporting product enables firms to operationalize the consensus-driven Endoxa ruleset. https://bit.ly/4cnhhfa #regulatoryreporting #SECrules #shareholderdisclosure
Droit’s Post
More Relevant Posts
-
Consisting of some of the largest and most sophisticated financial institutions, the Endoxa consortium is methodically analyzing the complexities of SEC Rule 13f-2 and working to find clarity around common use cases. Droit’s Position Reporting product enables firms to operationalize the consensus-driven Endoxa ruleset. Download our product sheet to learn more. https://bit.ly/3VdHjdG #regulatoryreporting #SECrules #shareholderdisclosure
-
-
Consisting of some of the largest and most sophisticated financial institutions, the Endoxa consortium is methodically analyzing the complexities of SEC Rule 13f-2 and working to find clarity around common use cases. Droit’s Position Reporting product enables firms to operationalize the consensus-driven Endoxa ruleset. Learn more here: https://bit.ly/3VdHjdG #regulatoryreporting #SECrules #shareholderdisclosure
-
-
As the regulatory landscape continues to evolve rapidly, I recently shared my thoughts on the need for a compliance overhaul. The complexity of these changes is a burden for both buy-side and sell-side institutions. Read Droit’s latest blog and learn about using our technology to operationalize consensus interpretations from the Endoxa consortium. https://bit.ly/3VttQzK
-
-
Sales Leader I Sales Coach I Entrepreneur I GTM I Growth Strategy I Enterprise Software Sales
TGIF… a 3-min summary on Shareholding disclosure (SHD)/ Disclosure of interests(DoI) 👌 #fridaythoughts #endoxa Droit Richard Ayres Elliot Burgess Samuel Lee Arishma Ramzan #disclosureofinterest #DoI #shareholdingdisclosure #shd #positionreporting #regtech #fintech #compliance #regulatoryreporting #tgif #fridayreads
Endoxa aims to improve the quality of shareholder disclosure obligations and mitigate interpretation and implementation errors through machine-readable rule logic established through a consensus model. Our founder and CEO, Brock Arnason, discusses Endoxa, how consensus informs Droit's Position Reporting product, and how it can benefit your firm. Interested in learning more? https://bit.ly/3UnIx7l #shareholderdisclosure #positionreporting #endoxa
-
A broken medical cold chain can mean the loss of vital biologicals, and that’s something no one can afford! 🧊💉 That’s why we rigorously test every device right off the assembly line. We understand the critical importance of a reliable medical cold chain for healthcare professionals, and we’re committed to making sure our solutions deliver a great performance from day one. Don’t leave reliability to chance – trust us to keep things cool when it matters most! Learn more: https://ow.ly/xeQC50TOcQY #ColdChain #UncompromisingReliability #PrecisionTesting
-
-
Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/gZHXGAqi #ClinicalTrials #ChooseCalyx
-
-
Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/gQgaCc7N #ClinicalTrials #ChooseCalyx
-
-
Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/gde_Jbxu #ClinicalTrials #ChooseCalyx
-
-
Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/g2kdx35P #ClinicalTrials #ChooseCalyx
-
-
Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/g7KywqHi #ClinicalTrials #ChooseCalyx
-
Learn how Droit’s Position Reporting product enables firms to operationalize the consensus-driven Endoxa ruleset. https://bit.ly/4cnhhfa